[1]王存泽,方美琳,王凌,等.P糖蛋白抑制剂维拉帕米对米诺环素在小鼠体内药动学与脑组织分布的影响[J].福建医药杂志,2023,45(06):115-119.
　WANG Cunze,FANG Meilin,WANG Ling,et al.Impact of P-glycoprotein inhibitor verapamil on the pharmacokinetics and brain tissue distribution of minocycline in mice[J].FUJIAN MEDICAL JOURNAL,2023,45(06):115-119.
点击复制

P糖蛋白抑制剂维拉帕米对米诺环素在小鼠体内药动学与脑组织分布的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年06期
页码:
115-119
栏目:
基础研究
出版日期:
2023-12-15

文章信息/Info

Title:
Impact of P-glycoprotein inhibitor verapamil on the pharmacokinetics and brain tissue distribution of minocycline in mice
文章编号:
1002-2600(2023)06-0115-05
作者:
王存泽; 方美琳; 王凌1; 龚书榕2
福建医科大学省立临床医学院 福建省立医院药学部(福州 350001)
Author(s):
WANG Cunze;  FANG Meilin;  WANG Ling;  GONG Shurong
Department of Pharmacy, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China
关键词:
药物代谢动力学;  P糖蛋白;  米诺环素;  维拉帕米
Keywords:
pharmacokinetics;  P-glycoprotein;  minocycline;  verapamil
分类号:
R322
文献标志码:
A
摘要:
目的 分析P糖蛋白抑制剂维拉帕米对米诺环素在小鼠血浆与脑组织的药物代谢动力学影响,探讨P糖蛋白参与的米诺环素耐药与药物外排机制。方法 将192只小鼠随机分为对照组与维拉帕米组,每组各96只,按照米诺环素、维拉帕米临床剂量折算为小鼠实际给药量,维拉帕米组小鼠在取材前3 d灌胃给予维拉帕米1 mg/kg,第4天两组小鼠灌胃给药35 mg/kg米诺环素。给药后每组小鼠按照药物代谢动力学预设时间点获取血浆、脑组织样本。运用高效液相色-三重四极杆质谱法测定米诺环素血浆、脑组织药物浓度,绘制药物浓度-时间曲线,同时采用非房室模型获得药代动力学参数并计算米诺环素脑分布系数,最后对两组数据进行比较分析。结果 药代动力学分析结果显示,相较对照组,维拉帕米组小鼠在脑组织中米诺环素药峰浓度(Cmax)(1 266.3±248.7)ng/mL显著增大(P<0.001),平均驻留时间(MRT)(16.3±1.5)h显著延长(P<0.05),药物浓度-时间曲线下面积(AUC)(15 053.8±1 839.3)(h·ng/mL)显著增大(P<0.000 1),表观清除率(CL)显著降低(P<0.05)。血浆中,相比对照组维拉帕米小鼠AUC(18 872.7±1 462.3)(h·ng/mL)、Cmax(2 593.6±362.2)ng/mL显著增加(P<0.001),MRT(9.0±0.8)h也显著延长(P<0.05)。此外,维拉帕米组的脑部米诺环素分布系数(84.6±7.9)%显著升高(P<0.05)。 结论 P糖蛋白抑制剂维拉帕米预给药能够增加小鼠米诺环素血、脑药物的暴露程度,延长驻留时间,降低清除率,提高米诺环素的生物利用度,提示米诺环素可能为P糖蛋白的潜在底物。
Abstract:
Objective To investigate the impact of the P-glycoprotein inhibitor verapamil on the pharmacokinetics of minocycline in mouse plasma and brain tissue, with a focus on exploring the involvement of P-glycoprotein in minocycline resistance and drug efflux mechanisms.Methods A total of 192 mice were randomly divided into two groups: the control group and the verapamil group, with 96 mice in each group.Clinical doses of minocycline and verapamil were converted to appropriate dosages for mice.The verapamil group of mice received an oral administration of 1 mg/kg verapamil for three days before sample collection.On the fourth day, both groups of mice received oral administration of 35 mg/kg minocycline.The control group received oral minocycline without verapamil pretreatment.Blood plasma and brain tissue samples were collected at predetermined pharmacokinetic time points.High-performance liquid chromatography coupled with triple quadrupole mass spectrometry was employed to determine minocycline concentrations in blood plasma and brain tissue.Pharmacokinetic parameters were obtained using a non-compartmental model, and the minocycline brain distribution coefficient was calculated.Finally, a comparative analysis of the data from both groups was performed.Results In brain tissue, Pharmacokinetic analysis revealed significant increases in minocycline peak concentration(Cmax)(1 266.3±248.7)ng/mL, mean residence time(MRT)(16.3±1.5)h, and area under the curve(AUC)(15 053.8±1 839.3)(h·ng/mL)in verapamil-treated mice compared to the control group(P<0.05).The apparent clearance rate(CL)was significantly reduced in the verapamil group(P<0.05).In plasma, verapamil-treated mice showed significant increases in AUC(18 872.7±1 462.3)(h·ng/mL), Cmax(2 593.6±362.2)ng/mL(P<0.001), and prolonged MRT(9.0±0.8)h(P<0.05).Furthermore, the verapamil group exhibited a significantly elevated minocycline brain distribution coefficient(84.6±7.9)%(P<0.05).Conclusion Pre-treatment with the P-glycoprotein inhibitor verapamil can increase minocycline exposure in mouse plasma and brain tissue, prolong residence time, decrease clearance and enhance minocycline's bioavailability, indicating that minocycline may be a potential substrate of P-glycoprotein.

参考文献/References:

[1] Pallotto C, Fiorio M, D'Avolio A,et al.Cerebrospinal fluid penetration of tigecycline [J].Scandinavian Journal of Infectious Diseases,2014,46(1):69-72.
[2] Ray L,Levasseur K,Nicolau D P,et al.Cerebral spinal fluid penetration of tigecycline in a patient with acinetobacter baumannii cerebritis [J].Annals of Pharmacotherapy,2010,44(3):582-586.
[3] 梅昭,李玉玲,谭月晴,等.米诺环素的药动学、药效学及应用研究概述[J].中国药师,2022,25(4):693-697.
[4] Asadi A, Abdi M, Kouhsari E, et al.Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future[J].Journal of Global Antimicrobial Resistance,2020:161-174.
[5] Loscher W,Potschka H.Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases[J].Prog Neurobiol,2005,76(1):22-76.
[6] Potschka H, Loscher W.Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain[J].Neuroreport,2001,12(11):2387-2389.
[7] 袁斯远,孙金,刘金民.α细辛醚对大鼠脑微血管内皮细胞P糖蛋白表达与功能的影响[J].中国医学科学院学报,2020,42(1):1-6.
[8] Thomas H, Coley H M.Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting P-glycoprotein [J].Cancercontrol,2003,10(2):159-165.
[9] Zhang J, Sun T, Liang L, et al.Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin[J].Soft Matter, 2014,10(3): 438-445.
[10] Zhou S F.Structure,function and regulation of P-glycoprotein and its clinical relevance in drug disposition[J].Xenobiotica,2008,38(7/8):802-832.
[11] 穆庆轲.维拉帕米基于P糖蛋白影响芍药苷经皮吸收的研究[D].大连:大连理工大学,2022.
[12] Silva V, Gil-Martins E, Silva B, et al.Xanthones as P-glycoprotein modulators and their impact on drug bioavailability[J].Expert Opin Drug Metab Toxicol,2021,17(4): 441-482.
[13] Milane A,Fernandez C,Vautier S,et al.Minocycline and riluzole brain disposition: interactions with P-glycoprotein at the blood-brain barrier [J].J Neurochem, 2007, 103(1): 164-173.
[14] Schrickx J,Fink-Gremmels J.P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model [J].J Vet Pharmacol Ther, 2007, 30(1): 25-31.
[15] Lin JH, Yamazaki M.Role of P-glycoprotein in pharmacokinetics: clinical implications[J].Clinical Pharmacokinetics, 2003,42(1): 59-98.
[16] 李晓晖,白如冰,王艳霞,等.脑缺血急性期神经元上P糖蛋白的过表达调控机制的研究[J].中国临床药理学杂志,2023,39(9):1242-1246.

备注/Memo

备注/Memo:
基金项目:福建省卫生健康科研人才培养项目(2019-ZQN-12)
1 福建省立医院药学部; 2 通信作者,福建省立医院重症医学三科
更新日期/Last Update: 2023-12-15